Loading
A phase 1/2 trial of A2B395 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma and triple-negative breast cancer, run by A2 Biotherapeutics Inc., now recruiting.
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT06682793 by A2 Biotherapeutics Inc., with 240 participants planned, started 2025-05-22 and due to reach its primary completion in 2029-03-31. Interventions recorded: A2B395.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Colorectal cancer and the tag pipeline.
Shares A2 Biotherapeutics, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares A2 Biotherapeutics, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.